|3.57|| +0.05 / +1.42%|
Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.Vericel was founded on March 24, 1989 and is headquartered in Cambridge, MA.
|Dominick C. Colangelo||President & Chief Executive Officer|
|Daniel R. Orlando||Chief Operating Officer|
|Gerard J. Michel||Chief Financial Officer & VP-Corporate Development|
|David Recker||Chief Medical Officer|
|Ross Tubo||Chief Scientific Officer|